they promote proliferation in cancer cells. Mutations in BRaf are commonly found in cancer, and drugs targeting the enzyme are in clinical use. Of these, the type I inhibitor, SB590885 (SB), binds to the active conformation of BRaf, whilst dabrafenib has no activation state selectivity. Paradoxically, these inhibitors activate ERK1/2 in cancer cells by stimulating the cascade at low concentrations rather than inhibiting it. Our aim is to determine the effects of BRaf inhibitors on the ERK1/2 cascade in cardiomyocytes to establish whether they may activate the pathway in the hearts of patients undergoing cancer therapy. Methods Rat neonatal cardiomyocytes were exposed to dabrafenib or SB and the effects on activation of MKK1/2 or ERK1/2 examined by immunoblotting with antibodies to phosphorylated (i.e. activated) or total kinases. Raf activities were assayed using GST-MKK1 as a substrate. The effects on myocyte morphology were studied by immunostaining for myofibrillar proteins. Results Low concentrations of SB (0.1 mM) or dabrafenib (1 mM) enhanced ERK1/2 signalling, with SB having a greater effect than dabrafenib. Thus, cardiomyocytes are primed for paradoxical activation of ERK1/2 by BRaf inhibitors. One explanation for the Raf paradox is that BRaf forms homo or heterodimers with cRaf. Thus, a submaximal concentration of BRaf inhibitor may be sufficient to inhibit only one Raf protein and, since the kinase is locked in an active state, there is activation of the other Raf partner. Consistent with this, 0.1 mM SB increased activities of both BRaf and cRaf, although there was no significant increase in dimerization. High concentrations of SB or dabrafenib (1-10 mM) inhibited basal ERK1/ 2 activity in cardiomyocytes, but the inhibitory effect was only transient and levels returned to basal within 1 hour. Furthermore, high concentrations of SB activated ERK1/2 over prolonged periods (up to 24 hour). This was associated with an increase in cardiomyocyte size and myofibrillar organisation consistent with low level activation of the pathway promoting cardiomyocyte hypertrophy. In mouse hearts in vivo, dabrafenib and SB590885 enhanced MKK1/2 phosphorylation over 24 hour, and increased hypertrophic ANF and BNP mRNA expression markers, consistent with the cell data. Conclusions Cardiomyocytes are primed for Raf paradox signalling and BRaf inhibitors such as SB and dabrafenib activate ERK1/2 in cardiomyocytes. Consistent with a role for ERK1/2 in cardiomyocyte hypertrophy, SB increases expression of hypertrophic gene markers and promotes morphological changes associated with hypertrophy.
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ROLE OF SUMOYLATION AND DESUMOYLATION OF MITOCHONDRIAL FISSION PROTEINS IN MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY
Abstract 229 Figure 1 Results Levels of SENP3 were reduced in all three groups compared to control, with the greatest reduction seen during ischaemia (Fig 1A) . Despite the observed reduction in SENP3 levels no obvious change in overall levels of protein SUMO-2/ 3-ylation was detected in mitochondria fractions (Fig 1B) . An increase of SUMO-1 conjugation to an unidentified protein at about 55 kDa was observed during ischaemia and I/R compared to both the control and preconditioning groups (Fig  2A) . Intriguingly, in contrast to our finding in neurons, where mitochondrial partitioning of Drp1 decreases during ischaemia, in cardiac tissue we observed recruitment of Drp1 to mitochondria, with no change in total protein levels. Furthermore, Drp1 recruitment to mitochondria was increased by preconditioning. In the I/R group, in which cells are undergoing apoptosis, levels of Drp1 at the mitochondria are similar to controls (Fig 2B) .
Abstract 229 Figure 2
Conclusion Taken together our data suggest a delicate balance between SUMOylation and deSUMOylation that regulates the recruitment of Drp1 to mitochondria. This pathway plays an important role in the vulnerability of cardiomyocytes to ischaemic damage and myocardial reperfusion injury. Interestingly, the interplay between the relevant proteins appears to differ between heart and brain cells. Aim Late outgrowth endothelial cells (EOC) are strong contenders to be the true circulating endothelial progenitor cells since they are capable of clonogenic expansion, exhibit a mature endothelial phenotype, and contribute to angiogenesis in vivo. These cells may play a crucial role in the process of vascular repair, but whether they are able to accumulate at sites of vascular damage in vivo is not clear. We hypothesise that EOC, delivered locally or systemically, accumulate at, and incorporate into, a site of arterial injury. Methods Experimental groups comprised systemic administration of the glucose analogue radiotracer 18 F-Flurodeoxyglucose (FDG) (Sys-Free) or FDG-labelled EOC (Sys-EOC), or local administration of free FDG (Local-Free) or FDG-labelled EOC (Local-EOC). EOC were isolated from peripheral blood from patients with coronary heart disease (n=3). Left femoral artery injury was achieved in male Sprague Dawley rats (300-350g) under general anaesthesia by inserting micro-renathane tubing via the popliteal artery. EOC were labelled with FDG (25 MBq/ml, 30 min, 37°C) and 1 million cells were administered either locally into the femoral artery or systemically via the tail vein (0.3-1.3 MBq, n=3 per group). Following injection of radiolabelled cells or free FDG, rats underwent dynamic PET scanning over 4 hours (Mediso nanoPET/CT scanner, Hungary). AuroVist and Fenestra (MediLumine Inc, Canada) were used as computed tomography vascular contrast agents. Images were analysed with PMOD software (PMOD, Switzerland) and standardised uptake values were calculated. Results FDG radioactivity was successfully visualised by micro-PET/CT. The activity was distributed in the bladder, kidneys, heart, brain, lungs, spleen and liver (descending order). Radioactivity in the lungs was significantly higher (80 and 120 min) following systemic EOC administration compared with the other three groups (two-way ANOVA with Bonferroni posttest, p<0.001), and peak activity in the injured artery (55 min after administration) was significantly higher than in the noninjured right artery (two-way ANOVA with Bonferroni posttest, p<0.001). Following local EOC administration, radioactivity in the injured artery was significantly higher than in the non-injured right artery, or in the injured artery following local free FDG administration (two-way ANOVA with Bonferroni post-test, p<0.001). Radioactivity in the injured artery following local administration was considerably higher (~10 fold) than following systemic administration of either free FDG or labelled EOC. Conclusion Preliminary analysis shows that EOC are able to target sites of vascular injury following systemic and local administration. These observations suggest that late outgrowth endothelial cells have the potential to contribute to vascular repair and regeneration.
SUPER RESOLUTION IMAGING UNVEILING THE DYADIC ULTRASTRUCTURE IN ATRIAL AND VENTRICULAR CARDIOMYOCYTES
Lauren Toms*, Jessica Caldwell, Andrew Trafford, Katharine Dibb. University of Manchester 10. 1136/heartjnl-2017-311726.229 Calcium-induced calcium release drives contraction in cardiomyocytes. Located on the sarcoplasmic reticulum, ryanodine receptors (RyR) are responsible for the release of intracellular calcium stores. It has recently become apparent that the size and shape of RyR cluster may affect the functionality of that cluster, along with the relative distance to neighbouring clusters. Here, we compared the distribution of RyRs in the atria and ventricle.
